Dr. Leppik raised some important issues regarding the mechanism of action of zonisamide. There is a great deal of interest in the impact of zonisamide on the T-type calcium channel. However, the relevance of that mechanism to the clinical experience is not known. The drug's impact on the sodium channel is one that is not unique to this antiepilepsy drug (AED).
There is some unpublished scientific evidence about the impact of zonisamide on glutamate, a story that likely will continue to develop. Dr. Leppik cited the work of Dr. Miura and other investigators in Japan who have identified a link between the neuroprotective impact of zonisamide and some of the brain's methods of handling glutamate. There are six or seven different strategies that the brain uses to keep glutamate under control, and zonisamide may have an impact on one or two of those mechanisms. The Japanese investigators, and perhaps investigators around the world, will be looking more closely at this issue of neuroprotection. Dr. Leppik provided an introduction to this concept and we hope to see more information in the future.
As far as the pharmacokinetics of this drug, the half-life of zonisamide when combined with other drugs deserves attention. With zonisamide monotherapy or when zonisamide is given to a naive patient, the drug's half-life approaches 70 h. While the effects of other AEDs were discussed, experience with non-AED medications remains a question. For example, in the United States, assessing the potential for contraceptive failure due to an interaction between zonisamide and oral contraceptives is of particular interest. Since oral contraceptives have not until recently been available in Japan, contraceptive failure has not been an issue or an observation in Japan. However, it is certainly a very practical question in the United States. Contraceptive failure in patients taking AEDs is a disappointing experience, so it is very important to know of any potential interactions in advance.
The half-life of zonisamide is essentially cut in half by the concomitant use of liver enzymeinducing AEDs, particularly carbamazepine. The half-life of zonisamide drops to between 27 and 38 h when used with carbamazepine, phenytoin, or phenobarbital.
While zonisamide is not a cytochrome P 450 3A4 inducer, it may possibly induce other liver enzymes. The interaction with valproate was a curious observation, and the significance of this effect has not been determined. Valproate has a greater impact on the beta oxidation series than on the omega oxidation series, but it is not known whether that particular mechanism is operant in this case.
Red blood cell binding of zonisamide was discussed, and this binding can be very important in terms of plasma assay, as Dr. Leppik warns. Zonisamide is not the only drug that tends to sequester in red blood cells; there are others and hemolysis can be a problem.
